Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1993 Apr;92(1):114–119. doi: 10.1111/j.1365-2249.1993.tb05956.x

Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9.

L Milis 1, C A Morris 1, M C Sheehan 1, J A Charlesworth 1, B A Pussell 1
PMCID: PMC1554864  PMID: 7682159

Abstract

In the activated complement system, vitronectin (complement S-protein) occupies the metastable membrane binding site of the nascent precursor complex C5b-7, so that the newly formed SC5b-7 is unable to insert into cell membranes. Some evidence also indicates that vitronectin limits on-going membrane-associated pore formation by inhibiting C9 polymerization. It has been assumed that these two stages of terminal complement complex (TCC) inhibition take place through charge interactions between the heparin-binding region of vitronectin and homologous cysteine-rich sequences of the late complement proteins C6, C7, C8 and C9. We examined SC5b-7 formation and inhibition of C9 binding in the TCC using separate haemolytic assays. The mode of action of vitronectin in these assays was compared with two 15mer peptides which span residues 348-379 of the heparin-binding region, and a heparin-affinity polypeptide, protamine sulphate. The results showed that vitronectin acts predominantly through SC5b-7 production with a lesser effect on the inhibition of C9 lytic pore formation. In contrast, protamine sulphate did not prevent C5b-7 membrane attachment, but was a potent inhibitor of C9-mediated lysis. The peptides did not inhibit C5b-7 membrane insertion and only one affected C9 binding. These data suggest that the two stages of TCC inhibition involve separate binding sites on the vitronectin molecule. The site for association with nascent C5b-7 is unknown, whereas inhibition of C9 binding and pore formation takes place through the heparin-binding region.

Full text

PDF
114

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bhakdi S., Käflein R., Halstensen T. S., Hugo F., Preissner K. T., Mollnes T. E. Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes. Clin Exp Immunol. 1988 Dec;74(3):459–464. [PMC free article] [PubMed] [Google Scholar]
  2. Dalmasso A. P., Falk R. J., Raij L. The pathobiology of the terminal complement complexes. Complement Inflamm. 1989;6(1):36–48. doi: 10.1159/000463070. [DOI] [PubMed] [Google Scholar]
  3. Hayashi M., Akama T., Kono I., Kashiwagi H. Activation of vitronectin (serum spreading factor) binding of heparin by denaturing agents. J Biochem. 1985 Oct;98(4):1135–1138. doi: 10.1093/oxfordjournals.jbchem.a135363. [DOI] [PubMed] [Google Scholar]
  4. Ishikawa M., Hayashi M. Activation of the collagen-binding of endogenous serum vitronectin by heating, urea and glycosaminoglycans. Biochim Biophys Acta. 1992 May 22;1121(1-2):173–177. doi: 10.1016/0167-4838(92)90351-d. [DOI] [PubMed] [Google Scholar]
  5. Izumi M., Shimo-Oka T., Morishita N., Ii I., Hayashi M. Identification of the collagen-binding domain of vitronectin using monoclonal antibodies. Cell Struct Funct. 1988 Jun;13(3):217–225. doi: 10.1247/csf.13.217. [DOI] [PubMed] [Google Scholar]
  6. Jenne D., Stanley K. K. Molecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion. EMBO J. 1985 Dec 1;4(12):3153–3157. doi: 10.1002/j.1460-2075.1985.tb04058.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Murphy B. F., Saunders J. R., O'Bryan M. K., Kirszbaum L., Walker I. D., d'Apice A. J. SP-40,40 is an inhibitor of C5b-6-initiated haemolysis. Int Immunol. 1989;1(5):551–554. doi: 10.1093/intimm/1.5.551. [DOI] [PubMed] [Google Scholar]
  8. Podack E. R., Kolb W. P., Müller-Eberhard H. J. The SC5b-7 complex: formation, isolation, properties, and subunit composition. J Immunol. 1977 Dec;119(6):2024–2029. [PubMed] [Google Scholar]
  9. Podack E. R., Preissner K. T., Müller-Eberhard H. J. Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein. Acta Pathol Microbiol Immunol Scand Suppl. 1984;284:89–96. [PubMed] [Google Scholar]
  10. Preissner K. T., Grulich-Henn J., Ehrlich H. J., Declerck P., Justus C., Collen D., Pannekoek H., Müller-Berghaus G. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J Biol Chem. 1990 Oct 25;265(30):18490–18498. [PubMed] [Google Scholar]
  11. Preissner K. T. Structure and biological role of vitronectin. Annu Rev Cell Biol. 1991;7:275–310. doi: 10.1146/annurev.cb.07.110191.001423. [DOI] [PubMed] [Google Scholar]
  12. Seiffert D., Loskutoff D. J. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J Biol Chem. 1991 Feb 15;266(5):2824–2830. [PubMed] [Google Scholar]
  13. Suzuki S., Oldberg A., Hayman E. G., Pierschbacher M. D., Ruoslahti E. Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin. EMBO J. 1985 Oct;4(10):2519–2524. doi: 10.1002/j.1460-2075.1985.tb03965.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Tschopp J., Masson D. Inhibition of the lytic activity of perforin (cytolysin) and of late complement components by proteoglycans. Mol Immunol. 1987 Sep;24(9):907–913. doi: 10.1016/0161-5890(87)90002-2. [DOI] [PubMed] [Google Scholar]
  15. Tschopp J., Masson D., Schäfer S., Peitsch M., Preissner K. T. The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, and C9 and perforin from cytolytic T-cells and inhibits their lytic activities. Biochemistry. 1988 May 31;27(11):4103–4109. doi: 10.1021/bi00411a029. [DOI] [PubMed] [Google Scholar]
  16. Tschopp J., Mollnes T. E. Antigenic crossreactivity of the alpha subunit of complement component C8 with the cysteine-rich domain shared by complement component C9 and low density lipoprotein receptor. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4223–4227. doi: 10.1073/pnas.83.12.4223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Underwood P. A., Dalton B. A., Steele J. G., Bennett F. A., Strike P. Anti-fibronectin antibodies that modify heparin binding and cell adhesion: evidence for a new cell binding site in the heparin binding region. J Cell Sci. 1992 Aug;102(Pt 4):833–845. doi: 10.1242/jcs.102.4.833. [DOI] [PubMed] [Google Scholar]
  18. Yatohgo T., Izumi M., Kashiwagi H., Hayashi M. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct Funct. 1988 Aug;13(4):281–292. doi: 10.1247/csf.13.281. [DOI] [PubMed] [Google Scholar]
  19. de Boer H. C., Preissner K. T., Bouma B. N., de Groot P. G. Binding of vitronectin-thrombin-antithrombin III complex to human endothelial cells is mediated by the heparin binding site of vitronectin. J Biol Chem. 1992 Feb 5;267(4):2264–2268. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES